Compare Neurocrine Biosciences Inc (NBIX) vs VanEck Uranium & Nuclear ETF (NLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs VanEck Uranium & Nuclear ETF — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while VanEck Uranium & Nuclear ETF trades at $122.23. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, VanEck Uranium & Nuclear ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | NLR | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Sector/Thematic |
52-Week High | $185.50 | $164.37 |
52-Week Low | $123.10 | $102.70 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About VanEck Uranium & Nuclear ETF
VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.
Read more on NLR →
